Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RGNX |
---|---|---|
09:32 ET | 3430 | 13.56 |
09:36 ET | 100 | 13.59 |
09:38 ET | 100 | 13.66 |
09:41 ET | 1000 | 13.84 |
09:43 ET | 600 | 13.88 |
09:45 ET | 1152 | 13.87 |
09:48 ET | 100 | 13.885 |
09:50 ET | 800 | 13.875 |
09:52 ET | 4328 | 13.975 |
09:54 ET | 1011 | 13.86 |
09:56 ET | 300 | 13.81 |
09:57 ET | 3022 | 13.75 |
09:59 ET | 348 | 13.84 |
10:01 ET | 200 | 13.82 |
10:03 ET | 2700 | 13.84 |
10:08 ET | 100 | 13.83 |
10:10 ET | 100 | 13.85 |
10:12 ET | 500 | 13.9 |
10:14 ET | 302 | 13.83 |
10:15 ET | 300 | 13.82 |
10:17 ET | 1000 | 13.78 |
10:21 ET | 4298 | 13.75 |
10:24 ET | 495 | 13.69 |
10:26 ET | 500 | 13.695 |
10:28 ET | 958 | 13.72 |
10:30 ET | 1800 | 13.67 |
10:32 ET | 719 | 13.698 |
10:33 ET | 300 | 13.69 |
10:37 ET | 3273 | 13.71 |
10:39 ET | 300 | 13.73 |
10:42 ET | 350 | 13.76 |
10:44 ET | 100 | 13.73 |
10:46 ET | 100 | 13.695 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Regenxbio Inc | 693.5M | -2.3x | --- |
SAGE Therapeutics Inc | 636.7M | -1.2x | --- |
Zymeworks Inc | 641.3M | -5.1x | --- |
WAVE Life Sciences Ltd | 711.5M | -11.5x | --- |
Y-mAbs Therapeutics Inc | 525.7M | -24.1x | --- |
Urogen Pharma Ltd | 477.3M | -3.7x | --- |
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $693.5M |
---|---|
Revenue (TTM) | $86.7M |
Shares Outstanding | 49.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.29 |
EPS | $-5.88 |
Book Value | $7.08 |
P/E Ratio | -2.3x |
Price/Sales (TTM) | 8.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -306.52% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.